RPID CFO awarded shares and new warrant grants
RAPID MICRO BIOSYSTEMS, INC.
Rhea-AI Filing Summary
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes acquired 12,787 shares of Class A Common Stock in a registered direct offering at $1.955 per share, together with accompanying Series A and Series B warrants for 12,787 shares each.
The Series A Warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B Warrant has a $2.340 exercise price and expires on May 29, 2031. After these awards, he directly holds 568,981 shares of Class A Common Stock and 12,787 Series A and 12,787 Series B warrants. Both warrant series are subject to a 4.99% beneficial ownership cap on exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 38,361 shares
Grant/Award
3 txns
Insider
WIRTJES SEAN M
Role
CHIEF FINANCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series A Warrant (right to buy) | 12,787 | $0.00 | $0.00 |
| Grant/Award | Series B Warrant (right to buy) | 12,787 | $0.00 | $0.00 |
| Grant/Award | Class A Common Stock | 12,787 | $1.955 | $25K |
Holdings After Transaction:
Series A Warrant (right to buy) — 12,787 contracts (Direct);
Series B Warrant (right to buy) — 12,787 contracts (Direct);
Class A Common Stock — 568,981 shares (Direct)
Footnotes (2)
- F1. On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
- F2. The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Key Figures
Common shares acquired: 12,787 shares
Purchase price per share: $1.955 per share
Shares held after transaction: 568,981 shares
+5 more
8 metrics
Common shares acquired
12,787 shares
Class A Common Stock purchased in registered direct offering
Purchase price per share
$1.955 per share
Price for each share plus accompanying Series A and Series B Warrant
Shares held after transaction
568,981 shares
Total Class A Common Stock directly owned after acquisition
Series A Warrant size
12,787 warrants
Each exercisable into one share of Class A Common Stock
Series A Warrant exercise price
$1.955 per share
Exercise price for Series A Warrant into Class A Common Stock
Series B Warrant exercise price
$2.340 per share
Exercise price for Series B Warrant into Class A Common Stock
Beneficial ownership cap
4.99%
Maximum beneficial ownership allowed after warrant exercise
Series B Warrant expiration
May 29, 2031
Final expiration date of the Series B Warrant
Key Terms
registered direct offering, Series A Warrant, Series B Warrant, Rule 16(b)-3, +2 more
6 terms
registered direct offering financial
"purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Series A Warrant financial
"an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock"
A Series A warrant is a contract issued alongside a company’s early funding round that gives the holder the right to buy a set number of shares later at a fixed price. Think of it like a coupon that lets an investor purchase stock at today’s agreed price even if the company’s value rises; it can boost potential upside for the warrant holder and create dilution for existing shareholders, so investors watch them when assessing ownership and future share value.
Series B Warrant financial
"an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock"
A Series B warrant is a tradable right issued alongside a Series B funding round that lets its holder buy a specified number of company shares at a fixed price for a set period. It matters to investors because exercising the warrant increases the total shares outstanding (dilution) and can be a cheap way to gain ownership if the company’s value rises — think of it like a coupon to buy stock later at today’s price.
Rule 16(b)-3 regulatory
"approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3"
Section 13(d) regulatory
"beneficial ownership would be aggregated for purposes of Section 13(d) of the Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.
beneficially own financial
"would beneficially own more than 4.99% of the total number of shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RPID CFO Sean M. Wirtjes acquire in this Form 4 filing?
Sean M. Wirtjes acquired 12,787 shares of Class A Common Stock and accompanying Series A and Series B warrants. Each warrant series covers 12,787 underlying shares as part of a registered direct offering at a combined purchase price of $1.955 per share.
What are the key terms of the RPID Series A Warrant received by the CFO?
The Series A Warrant covers 12,787 shares of Class A Common Stock at a $1.955 exercise price. It becomes exercisable on November 29, 2026 and expires on May 29, 2027, subject to a 4.99% beneficial ownership limitation on post-exercise holdings.
What are the key terms of the RPID Series B Warrant reported in this filing?
The Series B Warrant covers 12,787 shares of Class A Common Stock at a $2.340 exercise price. It becomes exercisable on November 29, 2026 and expires on May 29, 2031, and is also subject to the 4.99% beneficial ownership limitation on exercise.
What is the 4.99% beneficial ownership limitation mentioned for RPID warrants?
The Series A and Series B Warrants cannot be exercised if doing so would cause the holder and affiliates to beneficially own more than 4.99% of outstanding Class A Common Stock immediately after exercise. This cap limits how many shares can be issued through warrant exercises.
How was the issuance of RPID securities to the CFO approved?
The issuance of the Class A Common Stock and accompanying Series A and Series B Warrants was approved by the issuer’s compensation committee. The approval was made in accordance with Rule 16(b)-3 under the Securities Exchange Act of 1934, as disclosed in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
